Search
Apadamtase alfa
go.drugbank.com/drugs/DB15164ApprovedInvestigational[A262071] Apadamtase alfa, sold under the brand name Adzynma (ADAMTS13, recombinant-krhn), was approved by the FDA in November 2023 for use as an enzyme replacement therapy in patients with cTTP. … for cleaving large von Willebrand factor multimers and preventing the formation of microthrombi - this deficiency in ADAMTS13 is responsible for the microangiopathic complications associated with cTTP
Elexacaftor
go.drugbank.com/drugs/DB15444ApprovedInvestigational[A187361] It received FDA approval in October 2019 in combination with [tezacaftor] and [ivacaftor] as the combination product Trikafta<sup>TM</sup>. … [A187361] While dual corrector/potentiator combination therapy has proven useful in the treatment of a subset of CF patients,[A187358] their use is typically limited to patients who are homozygous for
Cocamidopropyl betaine
go.drugbank.com/drugs/DB11350ApprovedCocamidopropyl betaine is used as a foam booster in shampoos, emulsifying agent, thickener, antistatic agent and rarely an antiseptic agent. … Cocamidopropyl betaine is a mixture of closely related organic compounds derived from coconut oil and dimethylaminopropylamine that typically acts as an amphoteric surfactant in cosmetics and personal
Categories: Compounds used in a research, industrial, or household settingEstradiol cypionate
go.drugbank.com/drugs/DB13954ApprovedVet approvedin potency and in estrogenic effects. … Because of the difference in potency between estradiol and estrone, menopause (and a change in primary hormone from estradiol to estrone) is associated with a number of symptoms associated with this reduction
Mixtures: OBAT SUNTIK KB IIPergolide
go.drugbank.com/drugs/DB01186ApprovedVet approvedWithdrawnWhile the use of pergolide in humans is still approved in only some countries, pergolide is mainly used for veterinary purposes. … The drug was withdrawn from the US market in March 2007 and from the Canadian market in August 2007.
Pirbuterol
go.drugbank.com/drugs/DB01291ApprovedWithdrawnin a concentration between 10-50%. … While it is recognized that beta-2 adrenergic receptors are the predominant receptors in bronchial smooth muscle, data indicate that there is a population of beta-2 receptors in the human heart, existing
Categories: Compounds used in a research, industrial, or household settingNelistotug
go.drugbank.com/drugs/DB19334InvestigationalNelistotug is under investigation in clinical trial NCT06062420 (A Platform Study of Novel Immunotherapy Combinations as First-line Treatment in Participants With PD-L1 Positive Recurrent/metastatic Squamous … Cell Carcinoma of the Head and Neck- GALAXIES H&N-202).
Nerandomilast
go.drugbank.com/drugs/DB18237ApprovedInvestigational[L54858] In the Phase 3 FIBRONEER-ILD trial, nerandomilast led to a smaller decline in forced vital capacity (FVC) than placebo over 52 weeks. [A274591] … [L54126] On October 7, 2025, nerandomilast was approved as the first new treatment for idiopathic pulmonary fibrosis in more than a decade.
Oteracil
go.drugbank.com/drugs/DB03209ApprovedInvestigationalApproved by the European Medicines Agency (EMA) in March 2011, Oteracil is available in combination with [DB09257] and [DB09256] within the commercially available product "Teysuno". … It functions by blocking the enzyme orotate phosphoribosyltransferase (OPRT), which is involved in the production of 5-FU.
Potassium alum
go.drugbank.com/drugs/DB09087ApprovedWithdrawn[L1070] It is an inorganic salt, also called potassium aluminum sulfate with a formula of AlK(SO4)2 that is predominantly produced in the dodecahydrate form (AlK(SO4)2 * 12H2O). … Potassium alum is formed by large, transparent crystals that are used in different products like food or drugs as a buffer, neutralizing or forming agent.[T60]